Effects of Candesartan on Left Ventricular Function, Aldosterone and BNP in Chronic Heart Failure

Purpose Heart failure (HF) is characterized by activation of neurohormonal systems such as aldosterone and natriuretic peptides. In the absence of published data, CandHeart trial was designed to assess the effects on left ventricular (LV) function, aldosterone and brain natriuretic peptide (BNP) of...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular drugs and therapy 2012-04, Vol.26 (2), p.131-143
Main Authors: Aleksova, Aneta, Masson, Serge, Maggioni, Aldo P., Lucci, Donata, Urso, Renato, Staszewsky, Lidia, Ciaffoni, Stefano, Cacciatore, Giuseppe, Misuraca, Gianfranco, Gulizia, Michele, Mos, Lucio, Proietti, Gianni, Minneci, Calogero, Latini, Roberto, Sinagra, Gianfranco
Format: Article
Language:English
Subjects:
Biological and medical sciences
Cardiology
Cardiology. Vascular system
Cardiovascular system
Heart
Heart failure, cardiogenic pulmonary edema, cardiac enlargement
Medical sciences
Medicine
Medicine & Public Health
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Heart failure (HF) is characterized by activation of neurohormonal systems such as aldosterone and natriuretic peptides. In the absence of published data, CandHeart trial was designed to assess the effects on left ventricular (LV) function, aldosterone and brain natriuretic peptide (BNP) of candesartan in patients with HF and preserved (LVEF ≥ 40%) or depressed (LVEF
ISSN:0920-3206
1573-7241
DOI:10.1007/s10557-012-6370-8